mRNA Vaccine Market Size & Share 2023 to 2032
Market Size by Type (Self-Amplifying mRNA Vaccines, Conventional Non-Amplifying mRNA Vaccines), End Use (Hospitals & Clinics.
Report ID: GMI6076
|
Published Date: June 2023
|
Report Format: PDF
Download Free PDF
Authors:
Mariam Faizullabhoy, Gauri Wani
mRNA Vaccine Market Size
mRNA Vaccine Market size accounted for USD 11.3 billion in 2022 and is estimated to grow at 9.6% to reach USD 27.7 billion by 2032. Rising prevalence of infectious disease, genetic disorders coupled with increasing awareness for vaccination is expected to boost the market growth.
mRNA Vaccine Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
For instance, according to World Health Organization (WHO), the COVID-19 pandemic lead to 4.5 million of deaths in 2020. Thus, evolution of viral and microbial variants and increasing R&D to combat drug-resistant infections is projected to foster the market expansion. Furthermore, growing awareness for vaccination among the population and availability of effective preventive vaccines offering immunity against infectious diseases will offer unprecedented growth opportunities to the market.
mRNA vaccines use messenger RNA (mRNA) molecules to deliver genetic instructions to cells in the body and produce an immune response. mRNA vaccines have gained significant attention and success during/post the COVID-19 pandemic. These vaccines offer several advantages including rapid development timelines, potential scalability, and the ability to induce strong immune responses. Additionally, mRNA vaccines holds promising potential for addressing various infectious diseases as well as applications in cancer immunotherapy and the treatment of genetic disorders has also been studied from several years.
COVID-19 Impact
The COVID-19 pandemic has shredded a limelight on the development of mRNA vaccines owing to unprecedented demand for COVID-19 vaccine. The need to curb the spread of the virus has prompted swift development and regulatory approvals for mRNA-based COVID-19 vaccines. For instance, in 2021, Pfizer-BioNTech vaccine received approval for the prevention of COVID-19 disease and showcased the immense potential of mRNA technology that helped to contain the spread of COVID-19 infection. This has led to increased investment and research in mRNA vaccine platforms, driving innovation and expanding the capabilities of the mRNA vaccine.
Moreover, the safety and efficacy of mRNA vaccines has led to collaborations and partnerships between pharmaceutical companies, governments and research institutions to ramp up development and production of mRNA vaccines, thereby positively influencing the market trends.
mRNA Vaccine Market Trends
The rising awareness and demand for vaccination coupled with the efficacy and potential of mRNA vaccines will significantly drive the market share. Growing awareness regarding vaccination for preventing infectious diseases and avoid epidemics and pandemics has led to a significant surge in mRNA-based vaccines. Also, mRNA vaccines offer high efficacy rates and have proven its potential to stimulate robust immune responses, providing enhanced protection against targeted pathogens. Further, rising government initiative and R&D activities to develop novel vaccines for various genetic disorders, autoimmune disease and various types of cancer is anticipated to fuel the industry outlook.
mRNA Vaccine Market Restraint
Stringent regulatory approval of mRNA vaccines can significantly hinder the market demand. The complex and rigorous regulatory requirements leads to delay the introduction of new vaccines and limit the entry of new players into the market. The unique nature of mRNA technology and its relatively recent entry into the market necessitates thorough evaluation and stringent regulatory oversight. Also, lengthy approval processes increase the time and costs associated with regulatory agencies with comprehensive data on safety, efficacy and manufacturing quality to ensure that mRNA vaccines meet the required standards.
mRNA Vaccine Market Analysis
By type, the mRNA vaccine market is classified into self-amplifying mRNA vaccines and conventional non-amplifying mRNA vaccines. The self-amplifying mRNA vaccines segment accounted for 50.9% of the business share in 2022 and is projected to witness robust growth over the analysis timeframe. The self-amplifying mRNA vaccines replicate within cells and enable to attain higher antigen production resulting in a more potent immune response and improved vaccine efficacy. Additionally, self-amplifying mRNA vaccines can achieve a dose-sparing effect requiring lower vaccine doses while still eliciting robust immune responses.
Furthermore, they offer flexibility in targeting various infectious diseases and can be adapted to express antigens from different pathogens, making it applicable to a range of viral, bacterial, parasitic diseases. Such advantages associated with self-amplifying mRNA vaccines is predictable to propel the market expansion.
The end-use in mRNA vaccine market is categorized into hospitals & clinics, research laboratories and other end-users. Hospitals & clinics segment accounted for USD 7.1 billion in 2022. Availability of skilled medical professionals and advanced healthcare infrastructure has propelled the hospitals & clinics segment progress. Also, hospitals offer accessibility and convenience for individuals seeking vaccination during their regular visits for healthcare needs. Furthermore, developed infrastructure and well-established storage facilities contributes to streamlined operations and reduces the risk of vaccine shortage as well as wastage in the hospital & clinics.
North America mRNA vaccine market accounted for over 42.4% revenue share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. The increasing prevalence of infectious diseases and rising adoption of advanced medical technologies is estimated to drive the market forecasts. Furthermore, presence of well-established healthcare infrastructure, key market players and research activities contribute to the growth of mRNA vaccine research & development. Moreover, growing demand for preventive healthcare, rising government investments in R&D will further support the of market growth in the North America region.
mRNA Vaccine Market Share
Major market players operating in the mRNA vaccine market include
These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
mRNA Vaccine Industry News:
The mRNA vaccine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By Type
End-use
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →